ArticleMolecular pharmaceutics2026
Combining Anti-Inflammatory Drugs and Cell-Specific Expression-Suppression Reduces the Adjuvant Activity of mRNA-LNPs.
Article in Molecular pharmaceutics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lipid nanoparticles (LNPs)-encapsulating mRNA (mRNA-LNPs) have become an important modality for vaccine development. mRNA-LNPs also have the ability to introduce therapeutic proteins, which suggests that they should also be a promising modality for gene therapy. However, the intrinsic adjuvant activity of mRNA-LNPs is a fundamental function of the LNPs in RNA vaccines, and this has shown a potential risk of inducing anti-transgene immunity when mRNA-LNPs were used in gene therapy. Therefore, a reduction in the adjuvant activity and adaptive immunity against an expressed protein are prerequisites for therapeutic applications. In this study, two strategies were combined to modulate the adjuvant activity of subcutaneously injected mRNA-LNPs: (1) loading a lipid derivative of dexamethasone to suppress inflammation and (2) inserting a sequence complementary to microRNA-142 into the mRNA to suppress gene expression in immune cells. The combination of these strategies reduced immune reactions against the model antigen ovalbumin in mRNA-LNPs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.